StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a research report sent to investors on Tuesday morning. The firm issued a hold rating on the biotechnology company's stock.
Separately, Northland Securities lowered Nabriva Therapeutics from an outperform rating to an underperform rating in a research note on Friday, January 6th.
Get Nabriva Therapeutics alerts:Nabriva Therapeutics Trading Down 0.5 %
Shares of NASDAQ:NBRV opened at $1.55 on Tuesday. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $13.65. The firm has a market capitalization of $47.49 million, a price-to-earnings ratio of -0.08 and a beta of 1.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.20 and a quick ratio of 1.40. The business's 50 day moving average price is $1.93 and its 200-day moving average price is $3.69.
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last released its quarterly earnings results on Thursday, November 10th. The biotechnology company reported ($4.21) earnings per share for the quarter, missing the consensus estimate of ($4.03) by ($0.18). Nabriva Therapeutics had a negative return on equity of 120.02% and a negative net margin of 133.25%. The company had revenue of $9.15 million for the quarter, compared to analyst estimates of $10.68 million. On average, equities research analysts forecast that Nabriva Therapeutics will post -17.37 earnings per share for the current fiscal year.Hedge Funds Weigh In On Nabriva Therapeutics
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned about 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. 0.23% of the stock is owned by hedge funds and other institutional investors.
Nabriva Therapeutics Company Profile
(Get Rating)
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Recommended Stories
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.